



1B-297-C100

## Monoclonal Antibody to CD34 Biotin conjugated (0.1 mg)

<b>Clone:</b>	4H11[APG]
<b>Isotype:</b>	Mouse IgG1
<b>Specificity:</b>	The antibody 4H11[APG] reacts with Class III epitope on CD34 (Mucosialin), a 110-115 kDa monomeric transmembrane phosphoglycoprotein expressed on hematopoietic progenitors cells and on the most pluripotential stem cells; it is gradually lost on progenitor cells. The antibody 4H11[APG] completely blocks binding of Class II antibody QBEnd10 and Class III antibodies BIRMA K3 and 8G12 on KG1a cell line. HLDA VI; WS Code M MA58
<b>Immunogen:</b>	Permanent human cell line derived from peripheral leucocytes of a patient suffering from chronic myeloid leukaemia.
<b>Species Reactivity:</b>	Human
<b>Preparation:</b>	The purified antibody is conjugated with Biotin-LC-NHS under optimum conditions. The reagent is free of unconjugated biotin.
<b>Concentration:</b>	1 mg/ml
<b>Storage Buffer:</b>	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
<b>Storage / Stability:</b>	Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
<b>Usage:</b>	Biotinylated antibody is designed for indirect immunofluorescence analysis by Flow Cytometry. Suggested working dilution is 1:200. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.
<b>Expiration:</b>	See vial label
<b>Lot Number:</b>	See vial label
<b>Background:</b>	CD34 is a highly glycosylated monomeric 111-115 kDa surface protein, which is present on many stem cell populations. It is a well established stem cell marker, though its expression on human hematopoietic stem cells is reversible. CD34 probably serves as a surface receptor that undergoes receptor-mediated endocytosis and regulates adhesion, differentiation and proliferation of hematopoietic stem cells and other progenitors. CD34 expression is likely to represent a specific state of hematopoietic development that may have altered adhering properties with expanding and differentiating capabilities in both in vitro and in vivo conditions.

**For laboratory research only, not for drug, diagnostic or other use.**



**Antibodies**

**References:**

- \*Krauter J, Hartl M, Hambach L, Kohlenberg A, Gunsilius E, Ganser A, Heil G: Receptor-mediated endocytosis of CD34 on hematopoietic cells after stimulation with the monoclonal antibody anti-HPCA-1. *J Hematother Stem Cell Res.* 2001 Dec;10(6):863-71.
- \*Dao MA, Arevalo J, Nolta JA: Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution. *Blood.* 2003 Jan 1;101(1):112-8.
- \*Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Gulati S, Luthra PM: Three-dimensional structure prediction of the interaction of CD34 with the SH3 domain of Crk-L. *Stem Cells Dev.* 2005 Oct;14(5):470-7.
- \*Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Luthra PM: Hematopoietic stem cell antigen CD34: role in adhesion or homing. *Stem Cells Dev.* 2006 Jun;15(3):305-13.
- \*Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).
- \*Elknerová K, Lacinová Z, Soucek J, Marinov I, Stöckbauer P: Growth inhibitory effect of the antibody to hematopoietic stem cell antigen CD34 in leukemic cell lines. *Neoplasma.* 2007;54(4):311-20.

**For laboratory research only, not for drug, diagnostic or other use.**